Utilizing extracellular vesicles as a drug delivery system in glaucoma and RGC degeneration.

Autor: Durmaz E; Cardiff University, School of Optometry & Vision Sciences, Cardiff, UK. Electronic address: DurmazE@cardiff.ac.uk., Dribika L; Cardiff University, School of Dentistry, Cardiff, UK., Kutnyanszky M; Cardiff University, School of Optometry & Vision Sciences, Cardiff, UK., Mead B; Cardiff University, School of Optometry & Vision Sciences, Cardiff, UK. Electronic address: MeadB@cardiff.ac.uk.
Jazyk: angličtina
Zdroj: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2024 Aug; Vol. 372, pp. 209-220. Date of Electronic Publication: 2024 Jun 22.
DOI: 10.1016/j.jconrel.2024.06.029
Abstrakt: Retinal diseases are the leading cause of blindness, resulting in irreversible degeneration and death of retinal neurons. One such cell type, the retinal ganglion cell (RGC), is responsible for connecting the retina to the rest of the brain through its axons that make up the optic nerve and is the primary cell lost in glaucoma and traumatic optic neuropathy. To date, different therapeutic strategies have been investigated to protect RGCs from death and preserve vision, yet currently available strategies are restricted to treating neuron loss by reducing intraocular pressure. A major barrier identified by these studies is drug delivery to RGCs, which is in large part due to drug stability, short duration time at target, low delivery efficiency, and undesired off-target effects. Therefore, a delivery system to deal with these problems is needed to ensure maximum benefit from the candidate therapeutic material. Extracellular vesicles (EV), nanocarriers released by all cells, are lipid membranes encapsulating RNAs, proteins, and lipids. As they naturally shuttle these encapsulated compounds between cells for communicative purposes, they may be exploitable and offer opportunities to overcome hurdles in retinal drug delivery, including drug stability, drug molecular weight, barriers in the retina, and drug adverse effects. Here, we summarize the potential of an EV drug delivery system, discussing their superiorities and potential application to target RGCs.
Competing Interests: Declaration of competing interest None.
(Copyright © 2023. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: